Evaluation of Delefilcon A and Senofilcon A Daily Disposable Toric Soft Contact Lenses Over Two Weeks of Wear
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Study Contact
- Phone Number: 1-800-843-2020
- Email: Bstraker@ITS.JNJ.com
Study Locations
-
-
Florida
-
Longwood, Florida, United States, 32779
- Omega Vision Center
-
Maitland, Florida, United States, 32751
- Maitland Vision Center - North Orlando Ave
-
-
Ohio
-
Granville, Ohio, United States, 43023
- Procare Vision Centers
-
Westerville, Ohio, United States, 43081
- Professional Vision Care Inc. - Westerville
-
-
Tennessee
-
Memphis, Tennessee, United States, 38111
- Optometry Group, LLC
-
-
Texas
-
Tyler, Texas, United States, 75703
- Tyler Eye Associates
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Potential subjects must satisfy all of the following criteria to be enrolled in the study.
The subject must:
- Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
- Appear able and willing to adhere to the instructions set forth in this clinical protocol.
- Be between 18 and 39 (inclusive) years of age at the time of screening.
- By self-report, habitually wear soft contact lenses in both eyes in a daily reusable or daily disposable wear modality (i.e., not extended wear modality). Habitual wear is defined as a minimum of 6 hours of wear per day, for a minimum of 2 days per week during the past four weeks.
- Possess a wearable pair of spectacles that provide correction for distance vision.
In both eyes, have refractive error suitable for correction with the toric contact lens powers available in this study:
- Sphere powers (DS) -1.50 through -4.00 in 0.25 steps
- Cylinder powers (DC) -0.75 and -1.25
- Axes (°) 170, 180, 10, 80, 90, 100
- Have best corrected monocular distance visual acuity of 20/30 or better in each eye.
Exclusion Criteria:
Potential subjects who meet any of the following criteria will be excluded from participating in the study.
The subject must not:
- Be currently pregnant or lactating.
- Be diabetic.
- Be currently using any ocular medications or have any ocular infection of any type.
- By self-report, have any ocular or systemic disease, allergies, infection, or use of medication that might contraindicate or interfere with contact lens wear, or otherwise compromise study endpoints, including infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive disease (e.g., Human Immunodeficiency Virus [HIV]), autoimmune disease (e.g., rheumatoid arthritis, Sjögren's syndrome), or history of serious mental illness or seizures. See section 9.1 for additional details regarding excluded systemic medications.
- Have habitually worn rigid gas permeable (RGP) lenses, orthokeratology lenses, or hybrid lenses (e.g., SynergEyes, SoftPerm) within the past 6 months.
- Be currently wearing monovision or multifocal contact lenses.
- Be currently wearing lenses in an extended wear modality.
- Have a history of strabismus or amblyopia.
- Be an employee (e.g., Investigator, Coordinator, Technician) or immediate family member of an employee (including partner, child, parent, grandparent, grandchild or sibling of the employee or their spouse) of the clinical site.
- Have participated in a contact lens or lens care product clinical trial within 7 days prior to study enrollment.
- Have clinically significant (grade 3 or higher on the FDA grading scale) slit lamp findings (e.g., corneal edema, neovascularization or staining, tarsal abnormalities or bulbar injection) or other corneal or ocular disease or abnormalities that contraindicate contact lens wear or may otherwise compromise study endpoints (including entropion, ectropion, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, moderate or above corneal distortion, herpetic keratitis).
- Have fluctuations in vision due to clinically significant dry eye or other ocular conditions.
- Have had or have planned (within the study period) any ocular or intraocular surgery (e.g., radial keratotomy, PRK, LASIK, iridotomy, retinal laser photocoagulation, etc.).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Test/Control
Eligible subjects who are habitual soft contact lens wearers will be randomized into the Test/Control sequence, to wear two different study lenses, one at a time, over two wear periods (test then control).
Each wear period will be approximately 2 weeks in duration, with a washout period of approximately 1 week between wear periods.
Subjects will be advised to wear the study lenses for a minimum of 8 hours per day on at least 5 days per week of each wear period.
|
Rotationally stabilized astigmatic soft contact lenses in senofilcon A containing a chromophore to filter High-Energy Visible Light (HEVL)
DAILIES TOTAL1® for Astigmatism Contact Lenses (DT1fA)
|
|
Experimental: Control/Test
Eligible subjects who are habitual soft contact lens wearers will be randomized into the Control/Test sequence, to wear two different study lenses, one at a time, over two wear periods (control then test).
Each wear period will be approximately 2 weeks in duration, with a washout period of approximately 1 week between wear periods.
Subjects will be advised to wear the study lenses for a minimum of 8 hours per day on at least 5 days per week of each wear period.
|
Rotationally stabilized astigmatic soft contact lenses in senofilcon A containing a chromophore to filter High-Energy Visible Light (HEVL)
DAILIES TOTAL1® for Astigmatism Contact Lenses (DT1fA)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of Eyes With Grade 3 or Higher Slit Lamp Findings
Time Frame: Up to 2-Week Follow-up
|
Slit Lamp Findings (SLF) were assessed using a biomicroscope and was graded using the FDA grading scale (Grade: 0, 1,2, 3 and 4) with grade 0 represents the absence of findings and 1 to 4 representing successively worse findings (i.e.
Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe).
This was performed on each subject eye at every study visit (baseline, unscheduled visits and 1-week follow-up, 2-week follow-up).
The data was then dichotomized into two groups.
Those with grade 3 or higher and those with grade 2 or lower.
The proportion of eyes with SLF with grade 3 or higher was reported for each lens.
|
Up to 2-Week Follow-up
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Johnson & Johnson Vision Care, Inc. Clinical Trial, Johnson & Johnson Vision Care, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- CR-6553
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ocular Physiology
-
NCT05427539Completed
-
NCT05291936Completed
-
NCT01663688Completed
-
NCT05502289Completed
-
NCT00991900Withdrawn
-
NCT00712764CompletedOcular Physiology | Microcirculation
-
NCT00712777WithdrawnIntraocular Pressure | Ocular Physiology
-
NCT00431392CompletedOcular Physiology | Regional Blood Flow
-
NCT00280501CompletedOcular Physiology | Regional Blood Flow
-
NCT00280462CompletedOcular Physiology | Regional Blood Flow
Clinical Trials on Senofilcon A contact lenses (TEST)
-
NCT02669095Completed
-
NCT02555098Completed
-
NCT05361304Completed
-
NCT02696317CompletedRefractive Error
-
NCT05101252Completed
-
NCT05222880Completed
-
NCT04889625Completed
-
NCT05805059Completed